Over $90 million raised to date from leading life science investors.
Organizations Involved
AbbVie, Lilly
Company Description
Syndeio Biosciences is pioneering precision neurotherapeutics focused on repairing and enhancing synaptic function in central nervous system (CNS) diseases. The company's clinical-stage pipeline and proprietary R&D platform are built on cutting-edge discoveries in synapse biology and translational biomarkers, with a mission to transform treatment for patients suffering from major depressive disorder (MDD), Alzheimer's disease, schizophrenia, and other synaptopathies.
Market
Neurotherapeutics
Location
Indianapolis,
Indiana,
United States
Coinvestors
Catalio Capital Management, Innoviva, Tenmile, Luson Bioventures, Palo Santo